Allergan stock has been volatile since the merger with Pfizer was abandoned due to Tax Inversion laws back in April 2016. After a April-August Pattern was successful in predicting a downtrend, there has been an emergence of a bullish pattern. Looking purely at technical's I see the stock hitting the 0.236 fib retracement before the earnings call scheduled for 2nd...
With broad market volatility ebbing, the place to sell premium is with earnings plays for now. Next week, look to put on options plays shortly before the earnings announcement to capitalize on post-announcement volatility contraction. This little fellahs currently look best for plays: LC: 5/9 (Monday) after market close. Due to the price of the underlying,...
Allergan Inc. finished last week on an indecisive note after a long downfall. Its previous rebound attempt was turned down by the systematic risk triggered by the macroeconomic news. The equity is currently trading near to its July's bearish trend, in blue. Unless the equity breaches 303.73, the bearish market is set to continue, with 280.56 as a primary...
Due to worse than expected ER, and lowered guidance, and top of all failed $AGN acquisition, it is very possible that $VRX is going to $90-$100 price level. Company is not profitable and even if their international profits rise (mostly Russia and Europe), there are problems in creating sustainable growth.